Forkhead box O1 transcription factor; a therapeutic target for diabetic cardiomyopathy

Area of Science:

• Cardiology
• Endocrinology
• Molecular Biology

Background:

• Diabetic cardiomyopathy (DbCM) is a leading cause of death in individuals with diabetes, characterized by ventricular dysfunction independent of vascular disease or hypertension.
• Multiple molecular factors contribute to DbCM, including insulin resistance, metabolic dysfunction, lipotoxicity, oxidative stress, and cell death pathways.

Purpose of the Study:

• To provide an overview of the role of the transcription factor FoxO1 in the molecular mechanisms underlying DbCM.
• To explore the therapeutic potential of targeting FoxO1-mediated pathways for treating diabetic cardiomyopathy.

Main Methods:

• Literature review and synthesis of existing research on FoxO1, diabetes, and cardiovascular function.
• Analysis of molecular pathways implicated in DbCM, focusing on FoxO1's involvement.

Main Results:

• Altered FoxO1 expression and activity are linked to cardiovascular complications in diabetes.
• FoxO1 plays a role in regulating energy metabolism, lipotoxicity, oxidative stress, and cell death in the context of DbCM.

Conclusions:

• FoxO1 is a key regulator implicated in the pathogenesis of diabetic cardiomyopathy.
• Targeting FoxO1 presents a promising therapeutic strategy for mitigating DbCM in both type 1 and type 2 diabetes.